Results 171 to 180 of about 2,499 (281)

What is the incidence and clinical significance of dry eye disease in patients treated with immune checkpoint inhibitors? A systematic review and meta‐analysis of ocular immune‐related adverse events

open access: yesActa Ophthalmologica, EarlyView.
Abstract Purpose Immune checkpoint inhibitors (ICIs) have transformed cancer therapy but may cause immune‐related adverse events (irAEs), including dry eye disease (DED). This study aimed to quantify the incidence of ICI‐associated DED and to evaluate factors contributing to variability across studies.
Kai‐Yang Chen   +2 more
wiley   +1 more source

Long‐term follow‐up of chronic central serous chorioretinopathy patients receiving oral eplerenone and half‐dose photodynamic therapy in the SPECTRA trial: SPECTRA trial report No. 4

open access: yesActa Ophthalmologica, EarlyView.
Abstract Purpose Assessing the 24‐month treatment outcome of half‐dose photodynamic therapy (PDT) or oral eplerenone in chronic central serous chorioretinopathy (cCSC). Methods Multicentre randomized clinical trial included cCSC patients from the SPECTRA trial who were randomized to receive half‐dose PDT or oral eplerenone.
Helena M. A. Feenstra   +8 more
wiley   +1 more source

Design of global climate control based on fuzzy systems with concept of carbon emissions. [PDF]

open access: yesPLoS One
Naseer S   +5 more
europepmc   +1 more source

Patient‐reported outcomes and visual function after four refractive strategies in cataract surgery: A randomized controlled trial

open access: yesActa Ophthalmologica, EarlyView.
Abstract Purpose To evaluate patient‐reported outcome measures (PROMs) and visual function across four groups of public cataract patients: emmetropia, mini‐monovision, monovision with partial‐range of field (RoF) narrow intraocular lenses (IOLs) and patients implanted with partial‐RoF extended IOLs.
Anne Guldhammer Skov   +4 more
wiley   +1 more source

Real‐world insights on switching aflibercept dosage for enhanced outcomes in age‐related macular degeneration (RISE‐AMD): Safety data

open access: yesActa Ophthalmologica, EarlyView.
Abstract Purpose To evaluate real‐world safety experience with aflibercept 8 mg in a large case series of patients with neovascular age‐related macular degeneration (nAMD). Methods Due to a high proportion of patients on short treatment intervals, patients with nAMD at a Danish tertiary retina clinic were systematically switched to aflibercept 8 mg ...
Mary Graciya Karunainathan   +12 more
wiley   +1 more source

Home - About - Disclaimer - Privacy